AAV UPF1
Alternative Names: AAV-hUPF1; AAV-UPF1Latest Information Update: 23 Apr 2024
At a glance
- Originator Brandeis University
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 23 Apr 2024 Preclinical development in Amyotrophic-lateral-sclerosis is ongoing in USA (Intrathecal, Injection) (MeiraGTx pipeline, April 2024)
- 31 Dec 2023 MeiraGTx has patent protection for ALS gene therapy program and the AAV-UPF1 in USA, Austria, Australia, Belgium, Denmark, France, Germany, Hong Kong, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland/Liechtenstein and United Kingdom before December 2023
- 31 Dec 2023 MeiraGTx has patents pending for ALS gene therapy program and the AAV-UPF1 in USA, Canada, Europe, Hong Kong before December 2023